The prevalence of LVH increased progressively across METS-VF quartiles, ranging from 7.9% to 31%. Higher METS-VF levels were ...
One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback